Parallax Volatility Advisers’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Parallax Volatility Advisers’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-353,227	Closed	-$30.1K	–	2698
2023 Q2	$30.1K	Sell	353,227 -72,152	-17%	-$5.84K	﹤0.01%	2114
2023 Q1	$17K	Sell	425,379 -23,907	-5%	-$1.85K	﹤0.01%	2346
2022 Q4	$12.4K	Sell	449,286 -379,522	-46%	-$14.2K	﹤0.01%	2536
2022 Q3	$47K	Buy	828,808 +238,201	+40%	+$14.3K	﹤0.01%	2626
2022 Q2	$53K	Buy	590,607 +159,522	+37%	+$35.4K	﹤0.01%	2460
2022 Q1	$155K	Buy	431,085 +107,943	+33%	+$47.6K	﹤0.01%	2264
2021 Q4	$162K	Buy	+323,142	New	+$182K	﹤0.01%	1686

Other funds holding CLDI.WS

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

EFI

EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return

ETH

Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return

Parallax Volatility Advisers's CLDI.WS Position: Q3 2023 in Review

Parallax Volatility Advisers sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q3 2023, closing a stake of 353,227 shares — an estimated $30.1K sold.

Parallax Volatility Advisers first reported a position in CLDI.WS in Q4 2021 and held it in 7 quarters. The position peaked at $162K in Q4 2021. 21 funds tracked by Wall St. Rank hold CLDI.WS as of Q3 2023.

Parallax Volatility Advisers reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q3 2023 after selling out during the quarter.
Parallax Volatility Advisers sold 353,227 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q3 2023, an estimated $30.1K.
Parallax Volatility Advisers first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q4 2021 and held it in 7 quarters.
Parallax Volatility Advisers's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $162K in Q4 2021.
21 funds tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q3 2023.

Based on Parallax Volatility Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.